Table 3.
Sociodemographic and clinical characteristics associated with not reaching the destination health facility among prisoners transferred out from the Mandalay central prison between 2011 and 2018.
| Characteristics | Total | Not Reached | (%) | RR | (95% CI) | aRR | (95% CI) |
|---|---|---|---|---|---|---|---|
| Total | 883 | 514 | (58.2) | ||||
| Age (years) | |||||||
| 15–29 | 338 | 202 | (59.8) | ref | Ref | ||
| 30–44 | 467 | 275 | (58.9) | 0.99 | (0.88–1.11) | 1.01 | (0.90–1.13) |
| ≥45 | 78 | 37 | (47.4) | 0.79 | (0.62–1.02) | 0.83 | (0.65–1.06) |
| Sex | |||||||
| Male | 809 | 488 | (60.3) | 1.72 | (1.25–2.35) * | 1.42 | (1.04–1.92) * |
| Female | 74 | 26 | (35.1) | ref | Ref | ||
| Mode of transmission | |||||||
| Heterosexual | 186 | 94 | (50.5) | ref | NE | ||
| PWID | 637 | 390 | (61.2) | 1.21 | (1.04–1.41) | ||
| Other | 23 | 12 | (52.2) | 1.03 | (0.68–1.57) | ||
| Unknown | 37 | 18 | (48.6) | 0.96 | (0.67–1.38) | ||
| Literate | |||||||
| No | 89 | 53 | (59.6) | 1.02 | (0.85–1.22) | 1.17 | (0.98–1.39) |
| Yes | 744 | 436 | (58.6) | ref | Ref | ||
| Missing | 50 | 25 | (50.0) | 0.85 | (0.64–1.13) | 1.07 | (0.82–1.40) |
| TB status at enrollment | |||||||
| No | 773 | 449 | (58.1) | ref | Ref | ||
| Yes | 107 | 63 | (58.9) | 1.01 | (0.86–1.20) | 1.16 | (0.97–1.39) |
| Missing | 3 | 2 | (66.7) | ||||
| Baseline WHO staging | |||||||
| Stage 1 & 2 | 517 | 323 | (62.5) | 1.19 | (1.06–1.34) * | 1.17 | (1.03–1.33) * |
| Stage 3 & 4 | 363 | 190 | (52.3) | Ref | Ref | ||
| Missing | 3 | 1 | (33.3) | ||||
| CD4 count (cells/µL) | |||||||
| < 200 | 291 | 154 | (52.9) | ref | Ref | ||
| 200–349 | 299 | 179 | (59.9) | 1.13 | (0.98–1.30) | 1.04 | (0.90–1.20) |
| 350–499 | 183 | 107 | (58.5) | 1.10 | (0.94–1.30) | 0.98 | (0.83–1.15) |
| ≥ 500 | 102 | 68 | (66.7) | 1.26 | (1.06–1.50) * | 1.17 | (0.99–1.39) |
| Missing | 8 | 6 | (75.0) | ||||
| Anaemia | |||||||
| No anaemia | 495 | 309 | (62.4) | ref | Ref | ||
| Mild | 211 | 113 | (53.6) | 0.86 | (0.74–0.99) * | 0.89 | (0.78–1.02) |
| Moderate | 138 | 72 | (52.2) | 0.84 | (0.70–0.99) * | 0.94 | (0.79–1.12) |
| Severe | 27 | 12 | (44.4) | 0.71 | (0.46–1.09) | 0.95 | (0.64–1.41) |
| Missing | 12 | 8 | (66.7) | 1.07 | (0.71–1.60) | 0.62 | (0.27–1.41) |
| Hepatitis B | |||||||
| Negative | 783 | 448 | (57.2) | ref | NE | ||
| Positive | 76 | 48 | (63.2) | 1.1 | (0.92–1.32) | ||
| Missing | 24 | 18 | (75.0) | 1.31 | (1.03–1.66) * | ||
| Hepatitis C | |||||||
| Negative | 247 | 127 | (51.4) | ref | Ref | ||
| Positive | 613 | 370 | (60.4) | 1.17 | (1.02–1.35) * | 0.91 | (0.80–1.05) |
| Missing | 23 | 17 | (73.9) | 1.44 | (1.10–1.89) * | 1.29 | (0.94–1.77) |
| BMI (kg/m2) | |||||||
| Underweight | 112 | 65 | (58.0) | 0.97 | (0.82–1.15) | NE | |
| Normal | 639 | 383 | (59.9) | ref | |||
| Overweight | 48 | 20 | (41.7) | 0.70 | (0.49–0.98) | ||
| Missing | 84 | 46 | (54.8) | 0.91 | (0.74–1.12) | ||
| Transferred-out site | |||||||
| IHC | 289 | 109 | (37.7) | ref | Ref | ||
| NAP | 560 | 371 | (66.3) | 1.76 | (1.50–2.06) * | 1.72 | (1.45–2.04) * |
| NGO | 34 | 34 | (100.0) | 2.65 | (2.29–3.08) * | 2.67 | (2.23–3.18) * |
Attrition, lost to follow-up or death; IHC, integrated HIV care program; follow-up, period of follow-up; IR, incident rate; RR, relative risk; aRR, adjusted relative risk; CI, confident interval; WHO, World Health Organization; CD4, cluster differentiation 4; µL, microliter; TB, tuberculosis; BMI, body mass index; kg/m2, kilogram per meter square; PWID, people who inject drugs; ref, reference; *, statistically significant with p value < 0.05; and NE, not estimated. BMI and mode of transmission were not included in the adjusted analysis due to collinearity with sex. Hepatitis B was not included due to collinearity with hepatitis C.